Home›People›Sean Zhang
SZ

Sean Zhang

Executive director at Vivo Capital, a healthcare-focused investment firm.

Director
Updated Nov 6, 2026·Latest SEC filing Nov 3, 2026·Suggest an edit

About Sean Zhang

Sean Zhang is an executive director at Vivo Capital, a healthcare-focused investment firm. Before that, he held the vice president role at Lilly Asia Ventures, focusing there on biotech venture investments and incubating new companies. Earlier, Sean worked as a management consultant with McKinsey & Company, advising pharma and biotech firms on R&D strategy, sales, marketing, and due diligence. He has also worked at biotech companies including Ocelot Bio and Allele Biotech.

Zhang is a director of Rgenta Therapeutics and a board observer at Zenas Biopharma. He also previously sat on the boards of ADARx Pharmaceuticals, Perfuse Therapeutics, and Proteologix.

Experience

This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Sean Zhang in the role, so the role may have started earlier or lasted longer.

Rgenta Therapeutics, Inc. Current
Director and promoter
2026 – Present · Woburn, MA
The company develops oral small-molecule drugs that target RNA to treat cancer and neurological diseases that current medicines cannot reach.
Vivo Capital Current
Executive Director
Zenas Biopharma Current
board observer
Lilly Asia Ventures
Vice President
McKinsey & Company
management consultant
ADARx Pharmaceuticals
member of the board of directors
Perfuse Therapeutics
member of the board of directors
Proteologix
member of the board of directors

Key Colleagues at Startups

The people Sean Zhang works with at each company, as listed on that company's latest Form D.

Rgenta Therapeutics, Inc. · Form D, Nov 3, 2026
HX
Hualin Xi
Co-founder and CEO, director
YF
Yichao Fan
Director
CK
Cillian King
Director and promoter
JK
Travis Wager
Travis Wager
Co-founder, President and CSO
ZW
Zhiping Weng
Director
Jeff Guckert
Jeff Guckert
Director of Finance

Sources

  1. SECRgenta Therapeutics, Inc. Form D, filed Nov 3, 2026